Prognosis for people with multiple primary melanomas compared with a single primary melanoma.

Competing Interests: Conflicts of interest Richard A Scolyer has received fees for professional services from MetaOptima Technology Inc., F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, GlaxoSmithKline. Scott W Menzies has received fees for advisory board participation from MoleMap Australia and Scibase AB. John F Thompson has received honoraria for advisory board participation from BMS Australia, MSD Australia, GSK and Provectus Inc, and travel and conference support from GSK, Provectus Inc and Novartis. Yuan Ni, Caroline G Watts, Christine Madronio, Bruce K Armstrong, Rachael L Morton, Graham J Mann, Anne E Cust, and Serigne N Lo have no conflicts of interest to declare.